PDCD1 and neoplasm: Subsequent flow cytometry analysis revealed that the combination therapy of STM2457 with anti‐PD‐1 reduced CD8+ T‐cell exhaustion in B16 tumours and significantly enhanced CD8+ T‐cell cytotoxicity by upregulating the expression of IFNγ and GzmB (Figure 2H).